Viewing nowCombinationSitacombi XR Tablet 100/1000 mg
Sitagliptin Hydrochloride Hydrate 113.4mg · Metformin Hydrochloride 1000mg
Tablet · Prescription medication · Combination
Ildong Pharmaceutical Co., Ltd.

MFDS item code 202201884 · Approved 2022.05.09 · Insurance code 642906770
Improves blood glucose control in patients with type 2 diabetes
This medication is used to help control blood sugar levels in patients with type 2 diabetes. It works by combining the effects of sitagliptin and metformin to complement dietary changes and exercise therapy. This allows for more effective control of blood sugar levels and assists in diabetes management. Patients can expect better treatment outcomes when consistently taking the medication and improving their lifestyle. In summary, this medication is used in the treatment of type 2 diabetes.
In antidiabetic therapy, the dose of this medicine should be determined by considering each patient's current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended daily doses of each component: sitagliptin 100 mg and metformin 2000 mg. This medicine should be taken once daily with a meal, preferably in the evening, and the dose should be increased gradually to reduce gastrointestinal adverse reactions caused by metformin. To maintain its extended-release properties, this medicine must be swallowed whole without splitting, crushing, grinding, or chewing. Cases have been reported in which this medicine was not completely dissolved and was excreted in the stool. It is not known whether the material excreted in the stool contains the active ingredients of the medicine. If a patient repeatedly reports finding this medicine in the stool, a healthcare professional should assess whether blood glucose is being adequately controlled (see Precautions for Use, 5. General Precautions). Take 1 tablet of this medicine 100/1000 mg extended-release tablet once daily. Patients taking this medicine 50/500 mg extended-release tablet or 50/1000 mg extended-release tablet should take 2 tablets together once daily. 1. Patients not currently treated with metformin: For patients with no prior experience of antidiabetic drug therapy whose blood glucose is not adequately controlled with monotherapy, or whose blood glucose cannot be adequately controlled with sitagliptin monotherapy, the initial total daily dose of this medicine is sitagliptin 100 mg and metformin 1000 mg. If blood glucose is not adequately controlled with the initial dose, the dose may be increased gradually up to the maximum recommended daily dose of metformin 2000 mg to reduce gastrointestinal adverse reactions caused by metformin. Patients with renal impairment who are receiving a reduced dose of sitagliptin should not be switched to this medicine (see Precautions for Use, 2. Patients Who Must Not Take This Medicine). 2. Patients treated with metformin: - For patients whose blood glucose is not adequately controlled with metformin monotherapy, the recommended initial total daily dose of this medicine is sitagliptin 100 mg and the patient's current metformin dose. - Patients switching from concomitant therapy with sitagliptin and metformin to this medicine may start at their current doses of sitagliptin and metformin. - Patients who have been taking immediate-release tablets at a dose of 850 mg or 1000 mg twice daily as their current metformin dose may start with 2 tablets of this medicine 50/1000 mg extended-release tablet once daily. 3. Patients whose blood glucose is not adequately controlled with concomitant therapy of metformin and a sulfonylurea, metformin and insulin, or metformin and a thiazolidinedione: The initial total daily dose of this medicine is sitagliptin 100 mg, and the initial dose of metformin should be determined by taking the patient's blood glucose level and current dose into consideration. The dose should be increased gradually to reduce gastrointestinal adverse reactions caused by metformin. When this medicine is used concomitantly with a sulfonylurea or insulin, a reduction in the dose of the sulfonylurea or insulin may be considered to reduce the risk of hypoglycemia induced by the sulfonylurea or insulin (see Precautions for Use, 5. General Precautions). No studies have been conducted to evaluate the safety and efficacy of switching to this medicine in patients previously treated with another oral antihyperglycemic agent. Any change in a type 2 diabetes treatment regimen may cause changes in blood glucose control; therefore, caution should be exercised and appropriate monitoring should be performed. Patients with renal impairment This medicine may be used in patients with moderate renal impairment, stage 3a (creatinine clearance [CrCl] ≥ 45 and < 60 mL/min or estimated glomerular filtration rate (eGFR) ≥ 45 and < 60 mL/min/1.73m2), provided they do not have other conditions that may increase the risk of lactic acidosis, with the following dosage adjustments. Treatment should not be initiated with this medicine because the starting dose of metformin is 500 mg or 850 mg once daily. The maximum recommended dose of metformin is 1000 mg per day. Renal function should be monitored carefully every 3-6 months. If renal function declines to CrCl < 45 mL/min or eGFR < 45 mL/min/1.73m2, this medicine should be discontinued immediately. Patients with hepatic impairment This medicine should not be administered to patients with hepatic impairment because it contains metformin (see Precautions for Use, 2. Patients Who Must Not Take This Medicine).
This medication contains both sitagliptin and metformin and is used for the treatment of type 2 diabetes. Firstly, the sitagliptin component can rarely cause severe allergic reactions such as anaphylaxis, angioedema, and serious skin conditions, so if any of these symptoms appear within 3 months of administration, use must be stopped immediately, and a doctor should be consulted. Additionally, sitagliptin carries a risk of inducing acute pancreatitis, and if symptoms such as abdominal pain, nausea, or vomiting occur, the medication should be discontinued immediately and medical attention sought. The metformin component can rarely lead to a serious side effect known as lactic acidosis, so it should not be used in patients with impaired kidney function, liver dysfunction, severe infections, or dehydration, especially in patients with reduced kidney function. This medication is contraindicated for patients with moderate to severe renal impairment, acute heart failure, acute myocardial infarction, severe infections and dehydration, pregnant or nursing women, and individuals with type 1 diabetes. During treatment, it is important to regularly monitor kidney function, and if sudden dehydration or deterioration of kidney function is suspected, administration should be stopped immediately. Furthermore, it is important to avoid alcohol consumption during treatment as it can increase the risk of lactic acidosis. Before and after surgery, this medication should be temporarily discontinued, and it can be resumed once the patient's oral intake and kidney function have returned to normal. This medication can cause hypoglycemia, so blood sugar levels should be carefully monitored, particularly if taken with insulin or sulfonylureas, which may require dosage adjustments. During treatment, side effects such as diarrhea, nausea, vomiting, abdominal pain, headache, and upper respiratory infections may occur, and if symptoms are severe or persistent, consultation with a physician is advised. This medication is not recommended for children (under 18 years) as its safety and effectiveness have not been established. Elderly patients may experience decreased kidney function, so it is advisable to regularly assess kidney function and to start at the lowest effective dose when taking this medication. Finally, regular blood tests, kidney function examinations, and vitamin B12 level assessments are important to monitor health while on this medication.
Severe allergic reactions, anaphylaxis, angioedema, Stevens-Johnson syndrome, acute pancreatitis, lactic acidosis, hypoglycemia, diarrhea, upper respiratory tract infection, headache, nausea, vomiting, abdominal pain, nasopharyngitis, constipation, arthralgia with severe and disabling conditions, blistering dermatosis, myalgia, limb pain, back pain, interstitial lung disease, pruritus, thrombocytopenia, rhabdomyolysis, elevated liver enzymes, acute renal failure, rash, urticaria, cutaneous vasculitis
Not everyone experiences these, and they can vary from person to person.
This medication should be stored in a tightly closed container to protect from air and moisture, at room temperature between 1 to 30 degrees Celsius. Proper storage will maintain the medication's effectiveness and ensure safe use.
Bright blue oval-shaped extended-release film-coated tablet with convex sides
28 tablets/bottle, 56 tablets/bottle, 200 tablets/bottle
Even with the same ingredient, strength, dosage form and how it is taken can differ.
Viewing nowCombinationSitagliptin Hydrochloride Hydrate 113.4mg · Metformin Hydrochloride 1000mg
Tablet · Prescription medication · Combination
Ildong Pharmaceutical Co., Ltd.
CombinationSitagliptin Hydrochloride Hydrate 56.7mg · Metformin Hydrochloride 500mg
Tablet · Prescription medication · Combination
Shinil Pharmaceutical Co., Ltd.
CombinationSitagliptin Hydrochloride Hydrate 56.7mg · Metformin Hydrochloride 1000mg
Tablet · Prescription medication · Combination
Shinil Pharmaceutical Co., Ltd.
CombinationSitagliptin Hydrochloride Hydrate 113.4mg · Metformin Hydrochloride 1000mg
Tablet · Prescription medication · Combination
Shinil Pharmaceutical Co., Ltd.
CombinationSitagliptin Hydrochloride Hydrate 56.7mg · Metformin Hydrochloride 500mg
Tablet · Prescription medication · Combination
GL Pharma Co., Ltd.
CombinationSitagliptin Hydrochloride Hydrate 56.7mg · Metformin Hydrochloride 1000mg
Tablet · Prescription medication · Combination
GL Pharma Co., Ltd.
CombinationSitagliptin Hydrochloride Hydrate 113.4mg · Metformin Hydrochloride 1000mg
Tablet · Prescription medication · Combination
GL Pharma Co., Ltd.
CombinationSitagliptin Hydrochloride Hydrate 56.7mg · Metformin Hydrochloride 500mg
Tablet · Prescription medication · Combination
Korea Hutech Pharmaceutical Co., Ltd.
Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.
No questions yet.
For anything that needs medical judgment, consult a doctor or pharmacist.
This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.